Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Aligos Therapeutics, Inc. (ALGS) had Weighted-Average Shares Outstanding (Diluted) of 10.35M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$0.96M |
|
$-15.86M |
|
-- |
|
$0.96M |
|
$19.53M |
|
$-18.57M |
|
$2.89M |
|
$-15.68M |
|
$-15.68M |
|
$-15.86M |
|
$-15.86M |
|
$-15.86M |
|
$-15.86M |
|
$-18.57M |
|
$-18.62M |
|
10.35M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
10.35M |
$-1.53 |
|
$-1.53 |
|
| Balance Sheet Financials | |
$127.94M |
|
$2.06M |
|
$6.76M |
|
$134.71M |
|
$20.27M |
|
$0.12M |
|
$12.57M |
|
$32.84M |
|
$101.87M |
|
$101.87M |
|
$101.87M |
|
6.15M |
|
| Cash Flow Statement Financials | |
$-36.41M |
|
$-83.49M |
|
$101.56M |
|
$37.11M |
|
$18.77M |
|
$-18.34M |
|
$2.12M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.31 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
100.00% |
|
-1924.04% |
|
-1924.04% |
|
-- |
|
-1624.66% |
|
-1643.83% |
|
$-36.56M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-15.57% |
|
-15.57% |
|
-11.78% |
|
-15.55% |
|
$16.56 |
|
$-3.53 |
|
$-3.52 |
|